Every pharmaceutical story has a point at which the stock price and the science finally line up, and for Merck, that point came on August 19, 2026. Following the company’s and Moderna’s announcement that their customized mRNA melanoma vaccine had achieved its Phase 3 objectives, shares surged 12.5 percent in a single session, adding about $43 billion in market value. In Merck’s lengthy history, it was one of the largest one-day initiatives. For many investors, the stock, which had been trading far below its potential for months, felt different.
You must comprehend the significance of Keytruda to Merck’s narrative in order to comprehend why that data landed so hard. In just the second quarter of 2026, the immunotherapy medication brought in $8.4 billion in sales, a 4% year-over-year increase that seems insignificant when you take into account the base from which it is expanding. Keytruda currently covers dozens of cancer indications, including head and neck tumors, lung cancer, and melanoma. The kind of pipeline development that excites oncologists and makes portfolio managers reach for spreadsheets is the notion that a customized mRNA vaccine, created especially for each patient’s tumor profile, could make Keytruda even more effective.
The Phase 3 trial, which included 1,137 patients with high-risk melanoma, demonstrated that the combination of the vaccine and Keytruda decreased the risk of cancer recurrence or spread when compared to Keytruda alone. A smaller study’s five-year follow-up data had previously indicated a 49% decrease in recurrence or metastasis. This is the first significant Phase 3 success for an mRNA cancer vaccine worldwide, as the signal has now been validated in a sizable late-stage trial. It’s difficult to ignore how important that is for the entire industry, not just Merck.
Merck’s stock reached a 52-week high of $154.49 a few days prior, and it began late August trading close to $150. The gain thus far this year is approximately 47%. For a stock that fell as low as $77.58 in the last 12 months, that is an incredible comeback. Approximately 76% of the shares are owned by institutional investors, and in recent quarters, a number of major companies significantly increased their holdings. While not necessarily concerning, a few insiders, including two executive vise presidents, sold shares in August at prices significantly below current levels. This is the kind of thing that should be taken into consideration when assessing the big picture.
On this issue, Wall Street is not speaking in unison. Goldman Sachs kept its buy rating while increasing its price target to $160. The stock was upgraded to Overweight by Morgan Stanley, with a $179 target. UBS raised its goal to $175. However, RBC Capital Markets took a different approach, downgrading Merck to Sector Perform and pointing out that the market might be undervaluing the 2028 Keytruda patent expiration. According to Jefferies, the stock has already priced in a large portion of the positive news, so he switched from Strong Buy to Hold. The disagreement is genuine and not irrational, but the consensus is generally favorable.
The question of valuation is truly complex. Merck’s intrinsic value is estimated by a discounted cash flow model to be close to $233 per share, suggesting significant growth from current levels. However, the price-to-earnings ratio is much higher than average for the pharmaceutical industry, at about 120 times trailing earnings. Both may be true simultaneously: the near-term multiple appears stretched, but the long-term cash flow story may be compelling. Before the Keytruda patent expires, it’s still unclear if the commercial rollout and approval process for the cancer vaccine will proceed swiftly enough to warrant that premium.
The pricing environment is another factor to take into account. Merck’s legal challenge to the Medicare Drug Price Negotiation Program was recently dismissed by a federal judge, who determined that the company’s involvement in Medicare and Medicaid agreements was voluntary. It’s a subtle but significant headwind. Although drug pricing reform in the US has been difficult, contentious, and politically complex, it doesn’t seem to be going away.
Over the last ten years, Merck has created something truly remarkable around Keytruda. A viable route to expanding that franchise into earlier-stage disease and potentially other cancer types is the melanoma vaccine program. The company has maintained its full-year guidance, and its quarterly revenue of $16.61 billion exceeded analyst expectations. There is a case here for investors who are prepared to wait until the patent expires and have faith in the pipeline. The reluctance is equally understandable for those who are concerned with near-term multiples and execution risk. Right now, Merck stock is essentially a wager on how oncology research will develop over the coming years.
